Skip to main content

Table 4 Five years (%) OS (overall survival), PFS (progression-free survival), (distant metastasis-free survival), LRRFS (locoregional relapse-free survival) and HRs with 95% CI

From: Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study

  CCRT plus cetuximab group (%) CCRT group (%) Hazard ratioa P value
N = 62 N = 124 (95% CI)  
Overall survival
 Deaths 6 11 _  
 Rate at 5 years 89.7% 90.7% 0.705 0.386
(81.9–97.5) (85.4–96.0) (0.318–1.560)
Progression-free survival
 Progression 13 19 _  
 Rate at 5 years 77.6% 84.5% 0.607 0.115
(66.6–88.5) (78.0–91.0) (0.324–1.137)
Locoregional relapse-free survival
 Locoregional relapses 3 7 _  
 Rate at 5 years 95.0% 94.0% 0.803 0.695
(89.5–100) (89.7–98.3) (0.269–2.403)
Distant metastasis-free survival
 Distant metastases 10 12 _  
 Rate at 5 years 82.0% 90.3% 0.489 0.068
(71.8–92.2) (85.0–95.6) (0.223–1.072)
  1. Data are n (%) or rate (95% CI). aHazard ratios were calculated with the unadjusted Cox proportional hazards model. P values were calculated with the unadjusted log-rank test